Home > Haematology > ASH 2019 > Sickle Cell Disease > Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

Presented By
Dr Niketa Shah, Yale University, USA
Conference
ASH 2019
In a small series of 13 older children with sickle cell disease, adding abatacept to the regimen after stem cell transplantation (SCT) appeared to be safe and effective to prevent graft-versus-host disease (GVHD) [1]. Dr Niketa Shah (Yale University, USA) presented the multicentre trial, which had a primary objective of determining event-free survival in patients treated with abatacept after SCT. The unmet need that the authors tried to address is that a major cause of mortality following unrelated donor SCT in sickle cell disease patients >13 years is GVHD. To that end, 13 children with sickle cell disease (ages 7-21 years) underwent SCT due to stroke (n=6), ≥3 severe vaso-occlusive pain crises (n=4), or ≥2 acute chest syndrome episodes per year (n=3). Patients received conditioning with hydroxyurea, proximal alemtuzumab (starting day −12 or earlier), fl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on